Advertisement

Topics

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

2014-08-27 03:35:47 | BioPortfolio

Summary

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy.

Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.

Description

see above

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Immunotherapy

Intervention

specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)

Location

Goethe University, Department of Pulmonology
Frankfurt
Hessen
Germany
60590

Status

Completed

Source

Johann Wolfgang Goethe University Hospitals

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:35:47-0400

Clinical Trials [583 Associated Clinical Trials listed on BioPortfolio]

Multicenter Trial of Immunotherapy With House Dust Mite Allergoid

Multicenter Immunotherapy House Dust Mite Allergoid

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

The Effect of Autologous Autovaccine in Patients With Allergy on House-Dust-Mite

House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. We test a possibility to immunize subjects sensitized against house dust m...

Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients

hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunot...

PubMed Articles [9372 Associated PubMed Articles listed on BioPortfolio]

Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites.

To observe the five-year efficacy of standardised specific subcutaneous immunotherapy for house dust mite allergy in monosensitised and polysensitised children with persistent allergic rhinitis.

SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.

Allergic rhinitis with or without conjunctivitis (AR/C) is common, necessitating evaluation of SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet efficacy in various subgroups.

Specific Immunotherapy in LAR: a randomized, double-blind placebo controlled trial with Phleum pratense subcutaneous allergen immunotherapy.

Allergen immunotherapy has been shown to be an effective treatment for local allergic rhinitis (LAR) to house dust mites. Studies with pollen allergen immunotherapy are limited to observational studie...

A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen Immunotherapy With House Dust Mites for Allergic Rhinitis.

House dust mites (HDM) are major allergens that cause allergic rhinitis (AR). Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to be clinically beneficial in many clinical trials. Su...

Immunotherapy of House Dust Mite Allergy.

House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergi...

Medical and Biotech [MESH] Definitions

Species of European house dust mite, in the family PYROGLYPHIDAE. It is the most commonly found house dust mite.

Species of American house dust mite, in the family PYROGLYPHIDAE.

Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans.

Earth or other matter in fine, dry particles. (Random House Unabridged Dictionary, 2d ed)

Family of house dust mites, in the superfamily Analgoidea, order Astigmata. They include the genera Dermatophagoides and Euroglyphus.

More From BioPortfolio on "Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Searches Linking to this Trial